HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Colistin (Coly-Mycin)

Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
Also Known As:
Coly-Mycin; Colimycin; Colisticin; Colistin Sulfate; Totazina; Sulfate, Colistin; Polymyxin E
Networked: 2679 relevant articles (277 outcomes, 390 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Li, Jian: 87 articles (06/2022 - 05/2003)
2. Nation, Roger L: 57 articles (01/2022 - 05/2003)
3. Velkov, Tony: 27 articles (05/2022 - 04/2010)
4. Falagas, Matthew E: 27 articles (04/2018 - 01/2005)
5. Rolain, Jean-Marc: 23 articles (12/2021 - 12/2008)
6. Wang, Yang: 21 articles (08/2022 - 01/2017)
7. Doi, Yohei: 18 articles (01/2022 - 08/2011)
8. Kaye, Keith S: 17 articles (07/2021 - 02/2011)
9. Zhou, Qi Tony: 16 articles (12/2021 - 10/2013)
10. Thamlikitkul, Visanu: 16 articles (02/2021 - 09/2007)

Related Diseases

1. Infections
01/01/2020 - "This observed intrinsic colistin resistance is of concern since this last-resort drug might no longer be effective for treating severe human infections with the most common Salmonella serovar, Salmonella enterica serovar Enteritidis. "
06/01/2016 - "Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?"
03/01/2015 - "Based on the above assessments, the quality of evidence presented for each outcome ranged from "very low" to "low." A significant improvement in clinical response (odds ratio, 1.57; 95% CI, 1.14-2.15; p = 0.006; I2 = 37%), microbiological eradication (odds ratio, 1.61; 95% CI, 1.11-2.35; p = 0.01; I2 = 0%), and infection-related mortality (odds ratio, 0.58; 95% CI, 0.34-0.96; p = 0.04; I2 = 46%) was observed with the addition of aerosolized colistin to i.v. treatment, whereas the addition of aerosolized colistin did not affect overall mortality (odds ratio, 0.74; 95% CI, 0.54-1.01; p = 0.06; I2 = 25%) or nephrotoxicity (odds ratio, 1.18; 95% CI, 0.76-1.83; p = 0.45; I2 = 0%). "
10/18/2023 - "coli infection model, co-administration of NCL195 and graded doses of colistin resulted in a dose-dependent significant reduction in colistin-susceptible (P < 0.01) or colistin-resistant (P < 0.05) E. "
01/01/2023 - "To further confirm this, we investigated the efficacy of combined GaNt and colistin in vitro using spot dilution and rapid time-kill assays and growth curve inhibition tests and in vivo using a murine lung infection model. "
2. Sepsis (Septicemia)
3. Critical Illness (Critically Ill)
4. Pneumonia (Pneumonitis)
5. Ventilator-Associated Pneumonia

Related Drugs and Biologics

1. Anti-Bacterial Agents (Antibiotics)
2. Carbapenems (Carbapenem Antibiotics)
3. Tigecycline (Tygacil)
4. Rifampin (Rifampicin)
5. Tobramycin (Nebcin)
6. Meropenem (Merrem)
7. Sulbactam
8. Imipenem
9. Fosfomycin
10. Polymyxin B (Aerosporin)

Related Therapies and Procedures

1. Therapeutics
2. Critical Care (Surgical Intensive Care)
3. Catheters
4. Artificial Respiration (Mechanical Ventilation)
5. Microspheres (Microsphere)